RT Journal Article
SR Electronic
T1 Post COVID-19 conditions in Children and Adolescents at 3 months following a Delta outbreak in Australia: a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.14.23287239
DO 10.1101/2023.03.14.23287239
A1 Britton, Philip N
A1 Burrell, Rebecca
A1 Chapman, Emily
A1 Boyle, Julia
A1 Alexander, Shirley
A1 Belessis, Yvonne
A1 Dalby-Payne, Jacqueline
A1 Knight, Katherine
A1 Lau, Christine
A1 McMullan, Brendan
A1 Milne, Bronwyn
A1 Paull, Marilyn
A1 Nguyen, Jonathan
A1 Selvadurai, Hiran
A1 Dale, Russell
A1 Baillie, Andrew
YR 2023
UL http://medrxiv.org/content/early/2023/03/15/2023.03.14.23287239.abstract
AB Background Long COVID remains incompletely understood in children and adolescents with scant Australian data available. We aimed to assess the impacts of the 2021 Delta variant of SARS-CoV-2 outbreak on symptoms and functioning 12 weeks post-acute infection in a cohort of children and adolescents.Methods The parents (or next of kin) of 11864 children and adolescents from a population catchment who had mandatory contact with Sydney Children’s Hospital Network facilities during acute SARS-CoV-2 infection (confirmed by PCR) were contacted by email or text message.Findings 1731 (17.7%) responded to an online survey assessing symptoms, functional impairment. 203 of the responders (11.7%) gave answers that were consistent with continued symptoms and/or functional impairment and were flagged for clinical review. Of the 169 subsequently clinically reviewed, many had already recovered (n=63, 37.3%) or had a pre-existing condition exacerbated by COVID-19 (18, 10.7%); 64 (37.9%) were diagnosed with a Post COVID Condition (PCC). Of these, a minority we considered to have features compatible with the United Kingdom consensus cases definition for Long COVID (n=21).Interpretation During an outbreak of the Delta variant of SARS-CoV-2 an online questionnaire with clinical review follow-up provided evidence that a majority of children with COVID-19 had complete recovery at 12 weeks post infection, but those with persisting symptoms demonstrated a wide spectrum of severity and phenotype that comprises a likely significant burden that warrants attention for individuals and at a population level.Funding New South Wales Health COVID-19 Emergency Response Priority Research Funding.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNew South Wales Health COVID-19 Emergency Response Priority Research FundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the Sydney Local health District (Royal Prince Alfred Hospital Zone) Human Research Ethics Committee (HREC ID: 2021/ETH11819 & X21-0370).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors